Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in 18F-FDG PET-CT scan.

Honguero Martínez AF, García Jiménez MD, García Vicente A, López-Torres Hidalgo J, Colon MJ, van Gómez López O, Soriano Castrejón ÁM, León Atance P.

Rev Esp Med Nucl Imagen Mol. 2016 May-Jun;35(3):159-64. doi: 10.1016/j.remn.2015.08.004. English, Spanish.

PMID:
26514322
2.

Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.

Lin JT, Yang XN, Zhong WZ, Liao RQ, Dong S, Nie Q, Weng SX, Fang XJ, Zheng JY, Wu YL.

Eur J Cardiothorac Surg. 2016 Nov;50(5):914-919.

PMID:
27113090
3.

Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.

Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.

Biomed Mater Eng. 2014;24(6):3091-103. doi: 10.3233/BME-141131.

PMID:
25227018
4.

Characteristics of Metastatic Mediastinal Lymph Nodes of Non-Small Cell Lung Cancer on Preoperative F-18 FDG PET/CT.

Lee AY, Choi SJ, Jung KP, Park JS, Lee SM, Bae SK.

Nucl Med Mol Imaging. 2014 Mar;48(1):41-6. doi: 10.1007/s13139-013-0244-2.

5.

Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.

Mattes MD, Moshchinsky AB, Ahsanuddin S, Rizk NP, Foster A, Wu AJ, Ashamalla H, Weber WA, Rimner A.

Clin Lung Cancer. 2015 Nov;16(6):e253-8. doi: 10.1016/j.cllc.2015.06.001.

PMID:
26163919
6.

The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients.

Koksal D, Demirag F, Bayiz H, Ozmen O, Tatci E, Berktas B, Aydoğdu K, Yekeler E.

J Cardiothorac Surg. 2013 Apr 4;8:63. doi: 10.1186/1749-8090-8-63.

7.

The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.

Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA.

Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23.

PMID:
15337041
10.

Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).

Ma Q, Liu D, Guo Y, Shi B, Song Z, Tian Y.

Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):342-8. doi: 10.3779/j.issn.1009-3419.2010.04.14.

11.

Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.

Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, Vera P.

J Nucl Med. 2015 Feb;56(2):196-203. doi: 10.2967/jnumed.114.144253.

12.

[Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with 
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].

Ren H, Xu W, You J, Song X, Huang H, Zhao N, Ren X, Zhang X.

Zhongguo Fei Ai Za Zhi. 2016 Apr 20;19(4):192-9. doi: 10.3779/j.issn.1009-3419.2016.04.03. Chinese.

13.

Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.

Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, Mancini M, Ardissone F.

Eur J Cardiothorac Surg. 2009 Sep;36(3):440-5. doi: 10.1016/j.ejcts.2009.04.003. Review.

PMID:
19464906
14.

Comparison of objective criteria and expert visual interpretation to classify benign and malignant hilar and mediastinal nodes on 18-F FDG PET/CT.

Nguyen P, Bhatt M, Bashirzadeh F, Hundloe J, Ware R, Fielding D, Ravi Kumar AS.

Respirology. 2015 Jan;20(1):129-37. doi: 10.1111/resp.12409.

15.

Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.

Okada M, Sakamoto T, Yuki T, Mimura T, Nitanda H, Miyoshi K, Tsubota N.

J Thorac Cardiovasc Surg. 2005 Apr;129(4):825-30.

16.

Measurement of primary tumor volume by PET-CT to evaluate risk of mediastinal nodal involvement in NSCLC patients with clinically negative N2 lymph nodes.

Lebioda A, Makarewicz R, Małkowski B, Dancewicz M, Kowalewski J, Windorbska W.

Rep Pract Oncol Radiother. 2013 Jan 5;18(2):76-81. doi: 10.1016/j.rpor.2012.11.002.

17.

Role of preoperative PET-CT in assessing mediastinal and hilar lymph node status in early stage lung cancer.

Lin WY, Hsu WH, Lin KH, Wang SJ.

J Chin Med Assoc. 2012 May;75(5):203-8. doi: 10.1016/j.jcma.2012.04.004.

18.

Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation.

Kumar A, Dutta R, Kannan U, Kumar R, Khilnani GC, Gupta SD.

Ann Thorac Med. 2011 Jan;6(1):11-6. doi: 10.4103/1817-1737.74270.

19.

FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.

Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ.

Lung Cancer. 2002 Feb;35(2):179-87.

PMID:
11804691
20.

Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.

Ohtaki Y, Shimizu K, Kaira K, Nagashima T, Obayashi K, Nakazawa S, Kakegawa S, Igai H, Kamiyoshihara M, Nishiyama M, Takeyoshi I.

Surg Today. 2016 Oct;46(10):1196-208. doi: 10.1007/s00595-015-1301-5.

PMID:
26782692
Items per page

Supplemental Content

Support Center